The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
c-Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma
Open accessAbstract
Aberrant vascularization is a hallmark of cancer progression and treatment resistance. Here, we have shown that endothelial cell (EC) plasticity drives aberrant vascularization and chemoresistance in glioblastoma multiforme (GBM). By utilizing human patient specimens, as well as allograft and genetic murine GBM models, we revealed that a robust endothelial plasticity in GBM allows acquisition of fibroblast transformation (also known as endothelial mesenchymal transition [Endo-MT]), which is characterized by EC expression of fibroblast markers, and determined that a prominent population of GBM-associated fibroblast-like cells have EC origin. Tumor ECs acquired the mesenchymal gene signature without the loss of EC functions, leading to enhanced cell proliferation and migration, as well as vessel permeability. Furthermore, we identified a c-Met/ETS-1/matrix metalloproteinase-14 (MMP-14) axis that controls VE-cadherin degradation, Endo-MT, and vascular abnormality. Pharmacological c-Met inhibition induced vessel normalization in patient tumor-derived ECs. Finally, EC-specific KO of Met inhibited vascular transformation, normalized blood vessels, and reduced intratumoral hypoxia, culminating in suppressed tumor growth and prolonged survival in GBM-bearing mice after temozolomide treatment. Together, these findings illustrate a mechanism that controls aberrant tumor vascularization and suggest that targeting Endo-MT may offer selective and efficient strategies for antivascular and vessel normalization therapies in GBM, and possibly other malignant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suggesting that pharmacologic c-Met inhibition might synergise with TMZ treatment and subsequent ICB in CRC.”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [156]
In the citing paper
“Of note, fibroblast-like endothelial cells within the tumour stroma of glioblastoma attenuate the efficacy of TMZ treatment and genetic loss of the hepatocyte growth factor receptor c-Met in endothelial cells synergised with TMZ treatment in a mouse model,156”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A. K., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,251
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V. E., Traverso, G., Romans, K. E., Montgomery, E. A., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,859
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Flagged first, then by citations
1 of the 49 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–127 of 127
Lv, X., Li, Q., Liu, H., Gong, M., Zhao, Y., Hu, J., Wu, F., & Wu, X. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17490 · Cited by 7
Crestani, M., Gerber, I., Miéville, A., Frauenknecht, K. B. M., Maragkou, T., Hortobágyi, T., & Viola Vogel, B. (2025) · Advanced Science · doi:10.1002/advs.202416526 · Cited by 6
Falchook, G. S., Battiste, J. D., Kalra, A., Shastry, M., Finney, L. H., Hoekstra, S., Shih, M. G., & Shih, K. C. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae220 · Cited by 5
Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma
Shiling, Z. H. O. U., Qian, S., Sun, B., Shi, P., Guo, S., Yang, C., Zhang, J., Gong, Y., & Yang, F. (2026) · Angiogenesis · doi:10.1007/s10456-026-10031-1 · Cited by 4
Self-citationLin, J., Wu, Y.-C., Yang, F., Tsai, J., Huang, D. Y., & Liu, W. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071161 · Cited by 4
Jenkins, S. V., Alimohammadi, M., Terry, A. S., Griffin, R. J., Tackett, A. J., Leung, J. W. C., Vang, K. B., Byrum, S. D., & Dings, R. P. M. (2021) · Angiogenesis · doi:10.1007/s10456-021-09771-z · Cited by 5
Cho, J. G., Hah, Y., Yun, E., Ka, H. I., Lee, A., Han, S., Lee, D., Kim, S. W., Park, J. H., Kwon, B. S., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70057 · Cited by 3
Multimodality Targeting of Glioma Cells
He, Z., Mitteer, R. A., Mou, Y., & Fan, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47660-7.00005-7 · Cited by 3
Self-citationHow the “seed” prepares the “soil”: the bone/bone marrow pre-metastatic niche
Maurizi, A., Ponzetti, M., & Rucci, N. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.74 · Cited by 2
Endothelial remodeling in osteosarcomas: insights from patient samples and in vitro studies
Legrand, M. A. (2025) · American Journal of Cancer Research · doi:10.62347/kyfo6159 · Cited by 2
Endothelial cell dysfunction in cancer: a not-so-innocent bystander
Ünlü, B., Joshi, N., & O’Sullivan, J. M. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.116 · Cited by 2
Yin, Z., Wang, Q., Xu, Z., Guo, K., & Wang, L. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2594783 · Cited by 1
Pericyte NNMT drives an immune-hostile vascular niche and restricts cancer immunotherapy
Wang, S., Ye, G., Zhang, C., Tan, L., Zhang, Z., Xu, X., chen, X., Zhang, Y., Xu, X., Pan, J., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.02.001 · Cited by 1
Self-citationZhou, W., Su, Y., Zhang, Y., Han, B., Liu, H., & Wang, X. (2020) · doi:10.21203/rs.3.rs-40867/v1 · Cited by 1
Mishra, G., Acharya, M., Pandit, A., Mohbey, K. K., & Sawant, D. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4907010/v1 · Cited by 1
Kikuchi, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737439418.793572281
Wei, W.-F., Zhou, H.-L., Chen, P.-Y., Huang, X.-L., Huang, L., Liang, L.-J., Guo, C.-H., Zhou, C.-F., Yu, L., Fan, L.-S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23639871
Wei, W.-F., Zhou, H.-L., Chen, P.-Y., Huang, X.-L., Huang, L., Liang, L.-J., Guo, C.-H., Zhou, C.-F., Yu, L., Fan, L.-S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23639874
Zhang, S., Fu, Z., Zhu, F., Gu, X., Wang, H., Cao, M., Guo, H., & Zhang, T. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02984-5
Yamamoto, H., Suzuki, H., Kaneko, M. K., & Kato, Y. (2026) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1177/21679436261441142
Gómez-Escudero, J., Maniati, E., Holdsworth, J., Beattie, G., Hijazi, M., Guelbert, M., Elorbany, S., Cutillas, P. R., Wang, J., Hodivala‐Dilke, K., et al. (2026) · Angiogenesis · doi:10.1007/s10456-026-10063-7 · Cited by 1
Nerve growth factor receptor (NGFR): A key player in glioblastoma progression
Kidder, B. M., Vengoji, R., Batra, S. K., & Shonka, N. A. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189645
Bennett, K. R., Vanrobaeys, Y. S., Teboh, T., Smith, Z., Scott, A., Hajal, C., Hammond, P. T., & Straehla, J. P. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71474
Fang, X., Wang, F., Li, H., Xiao, P., Wang, M., Wu, N., Yao, X., & Shi, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218824 · Cited by 2
The Roles of Transcription Factor Ets-1 in Neurological Disorders
Jantaratnotai, N., & McLarnon, J. G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06199-8
Liu, T., Chen, X., Sun, T., Wu, J., Yan, H., Liu, X., Lin, H., Wang, X., Xiao, Z., Xu, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.78208
Self-citationReframing cancer therapy through tumor plasticity
Shah, A. M., Marsh, B., & de Sauvage, F. J. (2026) · Nature Cancer · doi:10.1038/s43018-026-01232-0
Metadata
- Authors
- Huang, M., Liu, T., Ma, P., Mitteer, R. A., Zhang, Z., Kim, H. J., Yeo, E., Zhang, D., Cai, P., Li, C., Zhang, L., Zhao, B., Roccograndi, L., O’Rourke, D. M., Dahmane, N., Gong, Y., Koumenis, C., & Fan, Y.
- Affiliations
- University of Pennsylvania (US)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Shanghai University (CN)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-04-04
- Volume
- 126
- Issue
- 5
- Pages
- 1801-1814
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC4855929
- OpenAlex
- W2315035682
- Cited by
- 128
- References
- 49
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 13 · 2023: 15 · 2022: 12 · 2021: 15 · 2020: 16 · 2019: 9 · 2018: 13 · 2017: 7 · 2016: 3
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- University of Pennsylvania
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R00HL103792)
- National Cancer Institute (R01CA190415)
- National Institute of Neurological Disorders and Stroke (R01NS094533)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, c-Met, endothelial plasticity, endothelial-to-mesenchymal transition, tumor vascularization, chemoresistance, temozolomide resistance, ETS1, MMP-14, vessel normalization, intratumoral hypoxia, cancer-associated fibroblasts, antivascular therapy
- MeSH terms
- Temozolomide, Animals, Cell Movement, Dacarbazine, Female, Glioblastoma, Humans, Male, Neovascularization, Pathologic, Cell Hypoxia, Mice, Knockout, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Endothelial Cells, Cell Proliferation, Proto-Oncogene Protein c-ets-1, Mice, Matrix Metalloproteinase 14
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
